In a significant move aimed at addressing the critical shortage of viable donor organs, Illinois-based medical technology firm Bridge to Life has successfully closed a $110 million Series C equity financing round. This latest injection of capital brings the company’s total funding to approximately $160 million, signaling strong investor confidence in the future of organ preservation technology. The round was spearheaded by new investor Soleus Capital, with substantial participation from Lauxera Capital Partners and a consortium of private individual investors.
The funds are earmarked for a multi-faceted growth strategy: accelerating the domestic rollout of the company’s flagship VitaSmart hypothermic oxygenated perfusion (HOPE) system, scaling international operations, and driving the research and development of a broader pipeline of transplantation technologies.
The Technological Leap: Transforming Liver Transplantation
At the heart of Bridge to Life’s mission is the VitaSmart system, a breakthrough in transplant medicine that addresses one of the most persistent challenges in the field: the degradation of organs during transit.
Traditional organ preservation relies on static cold storage, where an organ is kept in a chilled state until it reaches the recipient. While this method has been the standard for decades, it limits the window of time an organ remains viable and often necessitates the rejection of "marginal" organs—those from older donors or donors with specific health complications that might not survive the trauma of traditional cold storage.
The VitaSmart system, which received FDA de novo clearance in January 2026, utilizes HOPE technology. Unlike static storage, VitaSmart continuously pumps a specialized oxygenated preservation solution through the liver at temperatures maintained between 1°C and 10°C. This active perfusion process keeps the organ in a metabolically active, yet "dormant" state, significantly reducing ischemic injury and allowing clinicians to assess and rehabilitate marginal organs before transplantation.
A Chronology of Progress
Bridge to Life’s trajectory over the past two years has been marked by strategic acquisitions and regulatory milestones:
- December 2024: Bridge to Life completes the strategic acquisition of the VitaSmart perfusion system from its original developer, the Italian medical device manufacturer Medica SpA. This move consolidated the company’s position as a leader in organ preservation.
- November 2024: The company announces a global milestone, confirming that more than 5,000 liver perfusions have been performed worldwide using their proprietary HOPE technique in tandem with the VitaSmart platform.
- January 2026: The FDA grants de novo clearance to the VitaSmart system, making it the first and only technology of its kind authorized for use in liver transplantation in the United States.
- Q1 2026: The official US commercial launch of VitaSmart commences.
- March 2026: Duke University Hospital becomes the first transplant center in the United States to implement the VitaSmart system in a clinical setting.
- May 2026: The results of the pivotal "Bridge to HOPE" trial (NCT05045794) are published in the prestigious JAMA Surgery, providing clinical validation for the system’s efficacy.
Supporting Data: Clinical Validation and the "Marginal Organ" Gap
The efficacy of the VitaSmart system is grounded in robust clinical evidence. The Bridge to HOPE trial, which was instrumental in securing regulatory approval, demonstrated that the use of HOPE technology significantly expands the pool of available donor organs.
According to the findings published in JAMA Surgery, the perfusion system successfully mitigates the risks associated with marginal organs. By oxygenating the tissue during the transit period, the system reduces the rates of post-transplant complications, such as early allograft dysfunction. For the thousands of patients on US liver transplant waitlists, this technology represents more than just an engineering achievement; it is a life-saving intervention that effectively increases the "supply" of viable organs by making previously unsuitable donors usable.
Official Perspectives: Leadership on the Impact
Don Webber, President and CEO of Bridge to Life, expressed optimism regarding the company’s rapid market penetration. "The VitaSmart launch has outpaced our expectations," Webber stated. "We are seeing leading academic centers across the country adopting the system with great speed. This financing is not just about the present; it provides us with the necessary runway to meet this immediate demand while simultaneously advancing a robust pipeline that expands our capabilities beyond liver transplantation into other solid organs."
The backing from heavyweights like Soleus Capital and Lauxera Capital Partners suggests that the medical investment community views Bridge to Life as a cornerstone company in the growing "organ-on-a-machine" market. By investing in a field that bridges the gap between donor availability and patient survival, these firms are positioning themselves at the forefront of a paradigm shift in surgical care.
Strategic Implications and Future Outlook
The implications of this $110 million funding round extend far beyond the immediate commercialization of the VitaSmart system. Bridge to Life has outlined a clear roadmap for the next phase of its evolution:
1. Expanding the Field Team
A significant portion of the capital will be directed toward bolstering the company’s field operations. The nature of high-end transplant technology requires specialized technical support. By increasing its field team, Bridge to Life ensures that transplant centers receive hands-on training and real-time support, which is critical for the adoption of new, complex clinical workflows.
2. Diversification of the Pipeline
The company is not content with limiting its impact to the liver. Bridge to Life has signaled that it is developing a new tool specifically designed for the assessment of organ viability. This tool would allow surgeons to objectively measure the health of an organ before deciding whether to proceed with a transplant, potentially eliminating the guesswork currently involved in the process. Furthermore, the company is actively exploring applications for its perfusion technology for other solid organs, such as kidneys and lungs, which represent the largest segments of the transplant waiting list.
3. Scaling Global Operations
While the current focus is heavily weighted toward the US market following the 2026 FDA clearance, the company intends to use the capital to scale its global footprint. By establishing a more robust supply chain and regulatory presence in international markets, Bridge to Life aims to make its HOPE technology a global standard for organ preservation, potentially transforming outcomes for transplant patients worldwide.
Addressing the Crisis of Supply
The urgency behind Bridge to Life’s mission is underscored by the state of organ transplantation in the United States. With tens of thousands of patients on transplant waitlists, the mortality rate for those waiting for a donor organ remains a public health crisis. The current system is plagued by the high rate of organ discard—where healthy organs are deemed "too risky" due to time spent in transit or the condition of the donor.
By providing a technology that "rescues" these organs, Bridge to Life is effectively attacking the bottleneck of the transplant process. As clinical centers continue to report success stories using the VitaSmart system, the data is likely to influence future transplant protocols, potentially making HOPE-based perfusion a mandatory standard of care rather than an optional tool.
Conclusion
The successful $110 million Series C round marks a maturation point for Bridge to Life. Moving from a niche technology developer to a commercial-stage powerhouse, the company is now tasked with the challenge of scaling a complex medical device business. With the clinical validation of JAMA Surgery in their portfolio and the backing of top-tier investors, Bridge to Life is well-positioned to lead the next generation of transplant medicine.
As the company continues to refine its organ viability assessment tools and explore new organ categories, the medical community will be watching closely. If the results seen with the VitaSmart system in the liver can be replicated across other solid organs, the implications for global public health will be profound, offering a glimmer of hope to the thousands of patients waiting for the call that could change their lives.
About the Author
